Partner Eric Alan Stone spoke at the American Conference Institute’s 20th Paragraph IV Disputes Conference, honoring the 40-year anniversary of the Hatch-Waxman Act, on April 25, 2024. In a panel titled “The Economics of Pharmaceutical Patents in 2024: Understanding How the Next Ledge of the Patent Cliff Will Reshape PIV Strategy,” Eric discussed the potential economic implications of hundreds of small molecule drugs—including at least a half dozen blockbuster drugs—going off patent by 2026, as well as the effects on Hatch-Waxman litigation. 

Alongside panelists Alex Brill, Senior Fellow at the American Enterprise Institute and John Christopher Rozendaal, Director of Sterne Kessler and moderator Brian Malkin, Associate General Counsel of Teva Pharmaceuticals, Eric examined the current challenges and opportunities relative to the complexities of the projected patent cliff, pipeline replenishment, and the strategies brands and generics are employing to navigate these challenges. 

Eric’s patent practice spans the full range of biotechnology and pharmaceutical cases and represents innovators under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act.